Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
241-260 of 1,782 trials

Cholestatic Pruritus: Linerixibat Treatment Study

We are studying the long-term safety and tolerability of linerixibat for people with cholestatic pruritus due to primary biliary cholangitis. The trial also looks at how this treatment affects quality of life and itch relief.

Cholestatic PruritusPrimary Biliary Cholangitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Preventing Postoperative Pain in Children: Locoregional Analgesia Study

We are studying whether locoregional analgesia can help reduce long-term pain after orthopedic surgery in children. The trial compares pain levels and recovery outcomes between different pain management methods.

Postoperative Pain>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngology

Metastatic Non-Small Cell Lung Cancer: Pembrolizumab with Sacituzumab Govitecan

We are studying whether combining pembrolizumab with sacituzumab govitecan improves survival and quality of life for patients with metastatic non-small cell lung cancer. This trial compares the combination treatment to pembrolizumab alone.

Metastatic Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Hereditary Angioedema: OCTA-C1-INH Treatment Study

We are studying a new intravenous treatment for people with hereditary angioedema to see if it effectively relieves symptoms during acute attacks. The trial includes adolescents and adults, and also looks at safety and quality of life.

Hereditary Angioedema1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Pembrolizumab for Progressive Multifocal Leukoencephalopathy in Immunocompromised Patients

We are studying whether Pembrolizumab can help reduce the JCV viral load in the cerebrospinal fluid of immunocompromised patients with PML. This trial aims to understand its effects on neurological health and overall survival.

Progressive Multifocal Leukoencephalopathy (PML)6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesNeurology

Lung Cancer: Adagrasib Dosing Study

We are comparing two dosing schedules of adagrasib for patients with non-small cell lung cancer and a KRAS G12C mutation who have had previous treatments. The goal is to find out which regimen works better and is safer.

Non-small cell lung cancerEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Melatonin for Chronic Back Pain

We are studying whether melatonin can help reduce pain and improve sleep in people with chronic back pain. This trial compares melatonin to a placebo to see which is more effective.

Chronic Back Pain≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Rare Ovarian Cancer: Abemaciclib and Letrozole Study

We are investigating the effects of a new treatment combining abemaciclib and letrozole for women with estrogen receptor positive rare ovarian cancer. The study aims to understand how well this treatment works and its impact on quality of life.

Adult-type Granulosa Cell TumorLow-Grade Serous Ovarian Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Staphylococcus aureus Bacteremia: SNAP Trial

We are testing various treatment options for patients with Staphylococcus aureus bacteremia to see how they impact survival and other health outcomes. This study aims to improve care for those affected by this serious infection.

Staphylococcus aureus Bacteremia3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Cardiogenic Shock: Early Empagliflozin Treatment

We are studying if starting empagliflozin early helps patients with cardiogenic shock improve their heart function and reduce hospital visits. This trial compares the new treatment with standard care to see which is more effective.

Cardiogenic Shock3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Liver Surgery: Octreotide Study

We are investigating whether octreotide can reduce blood loss and improve stability during laparoscopic liver surgery. This study will help us understand its effects compared to a placebo.

Laparoscopic Hepatectomy Surgery>2 yearsEfficacy phase (II)Standard MedicinesHepatologyInternal MedicineOtolaryngology

Atopic Dermatitis in Children: Tralokinumab Treatment

We are studying whether a new treatment with tralokinumab and topical steroids helps children aged 2 to under 12 and infants aged 6 months to under 2 manage moderate-to-severe atopic dermatitis better than a placebo. The trial also looks at how this treatment affects daily life and skin health.

Atopic Dermatitis1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Breast Cancer-Related Lymphedema: Topical Tacrolimus Study

We are investigating whether a topical ointment can reduce swelling in patients with breast cancer-related lymphedema. This study compares the ointment to a placebo to see if it improves symptoms and quality of life.

Lymphedema1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineOncology

Community-Acquired Pneumonia: Amoxicillin vs. Amoxicillin/Clavulanate

We are studying whether amoxicillin alone is as effective as amoxicillin/clavulanate for treating pneumonia in hospitalized patients aged 65 and older. This research may help determine the best antibiotic treatment for older adults.

Community-Acquired Pneumonia in Elderly Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Systemic Lupus Erythematosus: Upadacitinib Study

We are investigating whether the oral medication upadacitinib can improve symptoms in adults with moderate to severe systemic lupus erythematosus. The study will also monitor its safety over time compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology

Advanced Cholangiocarcinoma: Futibatinib Study

We are studying the effects of futibatinib in patients with advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. The goal is to see if it helps improve their condition and to understand its safety.

Cholangiocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Periodontitis: Vitamin D3 Supplementation Study

We are testing whether vitamin D3 can improve gum health in people with periodontitis and low vitamin D levels. This study will help us understand its effects alongside standard gum treatments.

Periodontitis6-12 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesInternal MedicineOtolaryngology

Chronic Cutaneous Lupus Erythematosus: Anifrolumab Study

We are investigating whether anifrolumab can improve skin symptoms in adults with chronic cutaneous lupus erythematosus who haven't responded to other treatments. The study will compare its effects to a placebo over 24 weeks.

Cutaneous Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Fibrotic Interstitial Lung Disease: Morphine for Breathlessness

We are studying whether slow-release morphine can help reduce breathlessness and cough in patients with fibrotic interstitial lung disease. The goal is to see if it improves their overall quality of life.

Fibrotic Interstitial Lung Disease≤3 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePulmonology

Dementia Care: Benefits of Amyloid PET Imaging

We are exploring how amyloid PET imaging may improve care for people with dementia compared to standard diagnostic methods. This study aims to show its impact on important health outcomes.

Dementia>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry